|
DE69938931D1
(de)
|
1998-09-23 |
2008-07-31 |
Inst Virologie Teilrechtsfaehi |
Retrovirale partikel, geschützt gegen komplementvermittelte lyse
|
|
WO2001074861A2
(en)
|
2000-03-31 |
2001-10-11 |
Mayo Foundation For Medical Education And Research |
Compositions and methods for tissue specific gene regulation therapy
|
|
JP2005507927A
(ja)
|
2001-10-30 |
2005-03-24 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
パーキンソン病を処置するための方法および組成物
|
|
EP2339010B1
(en)
|
2002-05-01 |
2017-04-12 |
Miltenyi Biotec Technology, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
|
US20060045910A1
(en)
|
2004-09-02 |
2006-03-02 |
Ehringer William D |
Preserved fusogenic vesicles
|
|
GB0426641D0
(en)
|
2004-12-03 |
2005-01-05 |
Bioactive Protein Delivery The |
Protein delivery system
|
|
CN101065488A
(zh)
|
2005-01-20 |
2007-10-31 |
新加坡科技研究局 |
将核酸递送到外周神经元的方法
|
|
RS51324B
(sr)
|
2005-04-25 |
2010-12-31 |
Merial Ltd. |
Vakcine protiv nipah virusa
|
|
WO2007005244A1
(en)
|
2005-07-05 |
2007-01-11 |
The Regents Of The University Of California |
Henipavirus receptor and uses thereof
|
|
SI1960430T1
(sl)
*
|
2005-12-09 |
2015-01-30 |
Ucb Pharma, S.A. |
Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
|
|
US20120121650A1
(en)
|
2006-08-18 |
2012-05-17 |
Johnston Robert E |
Chimeric Virus Vaccines
|
|
EP1975239A1
(en)
|
2006-09-27 |
2008-10-01 |
Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer |
Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
|
|
WO2008071959A1
(en)
|
2006-12-12 |
2008-06-19 |
Oxford Biomedica (Uk) Limited |
Lentiviral vectors comprising micrornas
|
|
WO2008081008A1
(en)
*
|
2007-01-05 |
2008-07-10 |
University Of Zurich |
Method of providing disease-specific binding molecules and targets
|
|
CA2722238C
(en)
|
2008-04-22 |
2017-11-28 |
Life Sciences Research Partners Vzw |
Liver-specific nucleic acid regulatory elements and methods and use thereof
|
|
WO2010053489A1
(en)
|
2008-11-07 |
2010-05-14 |
Children's Hospital Medical Center |
Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems
|
|
RS53257B2
(sr)
|
2009-07-24 |
2018-06-29 |
Immune Design Corp |
Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
|
|
EP2498823B1
(en)
|
2009-11-13 |
2018-08-29 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Direct protein delivery with engineered microvesicles
|
|
EP2476754A1
(en)
|
2011-01-14 |
2012-07-18 |
Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts |
Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
|
|
AU2012249474A1
(en)
|
2011-04-28 |
2013-11-07 |
Stc.Unm |
Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
|
|
GB201121070D0
(en)
|
2011-12-07 |
2012-01-18 |
Isis Innovation |
composition for delivery of biotherapeutics
|
|
EP2615176A1
(en)
|
2012-01-11 |
2013-07-17 |
Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe |
Novel pseudotyped lentiviral particles and their use in the in vitro targeted transduction of undifferentiated pluripotent human embryonic stem cells and induced pluripotent stem cells
|
|
EP2844746A4
(en)
|
2012-03-26 |
2016-07-20 |
Univ California |
PSEUDOTYPIZED LENTIVIRES WITH NIPAH VIRUS COVERS AND METHOD OF USE THEREOF
|
|
CN105051192B
(zh)
|
2012-11-13 |
2020-04-17 |
科迪艾克生物科学公司 |
治疗剂的递送
|
|
KR20150131208A
(ko)
|
2013-03-13 |
2015-11-24 |
이미지냅 인코포레이티드 |
Cd８에의 항원 결합 구조체들
|
|
GB201313249D0
(en)
|
2013-07-25 |
2013-09-11 |
Isis Innovation |
Method
|
|
KR102396026B1
(ko)
|
2014-01-21 |
2022-05-09 |
안자리움 바이오사이언시스 아게 |
하이브리도좀, 이를 포함하는 조성물, 이의 제조 방법 및 이의 용도
|
|
GB201412494D0
(en)
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
|
FI3240805T3
(fi)
*
|
2014-12-15 |
2025-02-17 |
Univ California |
Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
|
|
WO2016138525A1
(en)
|
2015-02-27 |
2016-09-01 |
University Of Washington |
Polypeptide assemblies and methods for the production thereof
|
|
US20180135012A1
(en)
|
2015-05-13 |
2018-05-17 |
Rubius Therapeutics, Inc. |
Membrane-receiver complex therapeutics
|
|
WO2017151717A1
(en)
|
2016-03-01 |
2017-09-08 |
French Brent A |
Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
|
|
CU24649B1
(es)
|
2016-03-19 |
2023-02-13 |
Exuma Biotech Corp |
Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos
|
|
US11458097B2
(en)
|
2016-03-30 |
2022-10-04 |
The University Of North Carolina At Chapel Hill |
Biological agent-exosome compositions and uses thereof
|
|
EP3235908A1
(en)
*
|
2016-04-21 |
2017-10-25 |
Ecole Normale Superieure De Lyon |
Methods for selectively modulating the activity of distinct subtypes of cells
|
|
WO2017211945A1
(en)
|
2016-06-09 |
2017-12-14 |
Alma Mater Studiorum Universita Di Bologna |
Herpesvirus with modified glycoprotein h for propagation in a cell
|
|
CA3030003A1
(en)
|
2016-07-08 |
2018-01-11 |
F1 Oncology, Inc. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
WO2018022747A1
(en)
|
2016-07-26 |
2018-02-01 |
Senti Biosciences, Inc. |
Genetic erasers
|
|
EP3346001A1
(en)
*
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
JP2020503390A
(ja)
|
2017-01-09 |
2020-01-30 |
オイシン バイオテクノロジーズ， インコーポレイテッド |
治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法
|
|
CA3062426A1
(en)
|
2017-05-08 |
2018-11-15 |
Flagship Pioneering Innovations V, Inc. |
Compositions for facilitating membrane fusion and uses thereof
|
|
SG11202000073XA
(en)
*
|
2017-07-24 |
2020-02-27 |
Regeneron Pharma |
Anti-cd8 antibodies and uses thereof
|
|
US20210187018A1
(en)
|
2017-12-07 |
2021-06-24 |
Flagship Pioneering Innovations V, Inc. |
Cytobiologics and therapeutic uses thereof
|
|
AU2019215063B2
(en)
|
2018-02-01 |
2025-10-16 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing Factor VIII
|
|
AU2019222560B2
(en)
|
2018-02-17 |
2025-07-03 |
Flagship Pioneering Innovations V, Inc. |
Compositions and methods for membrane protein delivery
|
|
CA3100050A1
(en)
*
|
2018-05-11 |
2019-11-14 |
Lupagen, Inc. |
Systems and methods for closed loop, real-time modifications of patient cells
|
|
SG11202011015QA
(en)
|
2018-05-15 |
2020-12-30 |
Flagship Pioneering Innovations V Inc |
Fusosome compositions and uses thereof
|
|
CN112955174A
(zh)
|
2018-07-09 |
2021-06-11 |
旗舰先锋创新V股份有限公司 |
融合剂脂质体组合物和其用途
|
|
AU2019369498A1
(en)
*
|
2018-10-31 |
2021-05-20 |
Delinia, Inc. |
Multivalent regulatory T cell modulators
|
|
CN113631718A
(zh)
|
2018-11-14 |
2021-11-09 |
旗舰先锋创新V股份有限公司 |
用于特定隔室货物递送的组合物和方法
|
|
EP3880832A1
(en)
|
2018-11-14 |
2021-09-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
|
AU2019378883A1
(en)
|
2018-11-14 |
2021-06-03 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for T cell delivery
|
|
US20220008557A1
(en)
|
2018-11-14 |
2022-01-13 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for cns delivery
|
|
CA3152525A1
(en)
*
|
2019-09-03 |
2021-03-11 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
|
CA3178308A1
(en)
*
|
2020-03-31 |
2021-10-07 |
Sana Biotechnology, Inc. |
Targeted lipid particles and compositions and uses thereof
|
|
MX2023008081A
(es)
*
|
2021-01-11 |
2023-09-12 |
Sana Biotechnology Inc |
Uso de vectores virales dirigidos a cd8.
|
|
KR20240028975A
(ko)
*
|
2021-04-08 |
2024-03-05 |
사나 바이오테크놀로지, 인크. |
Cd8-특이적 항체 구조체들 및 이의 조성물
|